Finasteride Versus Dutasteride: A Real-World Economic Evaluation

    February 2007 in “ PubMed
    Thomas C Fenter, M. Chris Runken, Libby Black, Michael Eaddy
    TLDR Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
    The study conducted a real-world economic evaluation comparing dutasteride and finasteride for treating benign prostatic hyperplasia in male patients over 50 years old. Using data from over 45 million patients, it was found that patients treated with dutasteride incurred $20.50 less per month in medical costs compared to those treated with finasteride. This cost reduction was primarily due to lower inpatient hospitalization charges for dutasteride patients. The study suggested that healthcare plans should consider these cost differences alongside pharmaceutical expenditures when evaluating these two 5-alpha reductase inhibitors (5ARIs).
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

      community Hair Loss Drugs Ranked in Order of Efficacy

      in Research/Science  67 upvotes 2 years ago
      Dutasteride is likely the most effective treatment for male pattern baldness, followed by finasteride and minoxidil in various forms and dosages. Users discuss personal experiences, dosages, and potential side effects, with some considering combining treatments for better results.

      community Update: 4 Month progress on Fin/Min plus dermaroller

      in Progress Pictures  559 upvotes 1 year ago
      A user shared a 4-month update on their hair regrowth progress using finasteride, minoxidil, a dermaroller, ketoconazole shampoo, multivitamins, and biotin, and received positive reactions and inquiries from others. They also mentioned lifestyle changes such as quitting creatine, alcohol, and smoking, which may have contributed to their success.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    4 / 4 results